阿巴西普对比利妥昔单抗在类风湿关节炎相关间质性肺病中与较低死亡风险的关联:一项模拟目标试验
该模拟目标试验基于TriNetX美国协作网络数据库纳入2007至2024年诊断为类风湿关节炎相关间质性肺病(RA-ILD)的患者,经倾向性评分匹配后阿巴西普组与利妥昔单抗组各1615例。阿巴西普与较低的全因死亡风险(HR 0.689;95%CI 0.581-0.818)及较低的机械通气风险(HR 0.698;95%CI 0.521-0.934)相关。作者指出因临床医生可能优先将阿巴西普用于较轻的RA-ILD,不能排除适应证残余混杂,该关联不应解读为因果证据,需前瞻性随机试验确认。
要点
- 匹配后阿巴西普组与利妥昔单抗组各1615例,阿巴西普与较低全因死亡风险相关(HR 0.689;95%CI 0.581-0.818)。
- 阿巴西普与较低机械通气风险相关(HR 0.698;95%CI 0.521-0.934)。
- 排除合并其他结缔组织病患者后死亡风险结果一致(HR 0.679;95%CI 0.570-0.810)。
核心结论
- 在RA-ILD患者中,阿巴西普与利妥昔单抗相比与较低的死亡风险相关。
- 因临床医生可能优先将阿巴西普用于较轻的RA-ILD,不能排除适应证残余混杂,该关联不应解读为因果证据。
- 需前瞻性随机试验确认阿巴西普是否带来真正的生存获益。
研究设计与样本
- 采用TriNetX美国协作网络数据库设计模拟目标试验,纳入2007至2024年诊断为RA-ILD的患者。
- 使用倾向性评分匹配平衡阿巴西普组与利妥昔单抗组的基线特征,匹配后每组1615例。
- 主要结局为全因死亡,次要结局包括呼吸事件、医疗资源利用和感染相关不良事件,采用Cox比例风险模型估计HR及95%CI。
主要发现
- 匹配后阿巴西普组与利妥昔单抗组各1615例,阿巴西普与较低的全因死亡风险相关(HR 0.689;95%CI 0.581-0.818)。
- 阿巴西普与较低的机械通气风险相关(HR 0.698;95%CI 0.521-0.934)。
- 亚组分析结果一致。
- 排除合并其他结缔组织病患者后的敏感性分析结果一致(死亡:HR 0.679;95%CI 0.570-0.810)。
局限性
- 因临床医生可能优先将阿巴西普用于较轻的RA-ILD,不能排除适应证残余混杂。
- 该关联不应解读为因果证据。
- 需前瞻性随机试验确认阿巴西普是否带来真正的生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal treatment strategy for rheumatoid arthritis-associated interstitial lung disease (RA-ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA-ILD. METHODS: An emulated target trial was designed using the TriNetX US Collaborative Network database, including patients with RA-ILD, diagnosed between 2007 and 2024. Propensity score matching was used to balance baseline characteristics between the two treatment groups (abatacept and rituximab). The primary outcome was all-cause mortality, and secondary outcomes included respiratory events, medical utilization, and infection-related adverse events. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated to use Cox proportional hazards models. RESULTS: In total, 1,615 patients per group were identified after matching for analysis. Abatacept was associated with a significantly lower risk of all-cause mortality compared with rituximab (HR, 0.689; 95% CI, 0.581-0.818) and a reduced risk of mechanical ventilation (HR, 0.698; 95% CI, 0.521-0.934). The subgroup analyses yielded consistent findings. Sensitivity analyses excluding patients with concomitant connective tissue diseases also demonstrated consistent results (mortality: HR, 0.679; 95% CI, 0.570-0.810), reinforcing the robustness of the findings. CONCLUSION: Abatacept was associated with a lower risk of mortality compared with rituximab in patients with RA-ILD. Because clinicians may preferentially reserve abatacept for less aggressive RA-ILD, residual confounding by indication cannot be excluded; thus, the association should not be interpreted as proof of causality. Prospective randomized trials are needed to confirm whether abatacept confers a true survival advantage.
引用
- Shih PC, Wang SI, Wei JCC, et al. Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial. Arthritis Rheumatol. 2025. PMID: 40693411. doi:10.1002/art.43332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。